Literature DB >> 17679464

Mutational analysis of proapoptotic integrin beta 3 cytoplasmic domain in common human cancers.

Nam Jin Yoo1, Young Hwa Soung, Sung Hak Lee, Eun Goo Jeong, Sug Hyung Lee.   

Abstract

AIMS: Mounting evidence indicates that deregulation of apoptosis is involved in the mechanisms of cancer development. Integrins are cell adhesion receptors that mediate cell survival and migration. A recent study showed that unligated integrin beta 3 (ITGB3) induced apoptosis by recruitment of caspase-8. The aim of the present study was to explore the possibility that genetic alteration of the ITGB3 gene is involved in the development of human cancers possibly by inactivating the apoptosis function of ITGB3.
METHODS: We analyzed the coding region of the cytoplasmic domain of the human ITGB3 gene for the detection of somatic mutations in 100 gastric, 90 colorectal, 100 non-small cell lung, 43 urinary bladder and 50 head-neck cancers by a polymerase chain reaction-based, single-strand conformation polymorphism.
RESULTS: We found an identical ITGB3 mutation in two unrelated patient samples (one in colorectal and the other in bladder cancer). The ITGB3 mutation was a missense mutation which would substitute an amino acid (E757K).
CONCLUSIONS: The data suggested that the proapoptotic ITGB3 cytoplasmic domain is rarely mutated in common human cancers and may not play an important role in the development of the cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17679464     DOI: 10.1177/030089160709300309

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Integrin α5 Suppresses the Phosphorylation of Epidermal Growth Factor Receptor and Its Cellular Signaling of Cell Proliferation via N-Glycosylation.

Authors:  Qinglei Hang; Tomoya Isaji; Sicong Hou; Sanghun Im; Tomohiko Fukuda; Jianguo Gu
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

2.  Bcl-G acquitted of murder!

Authors:  D Tischner; A Villunger
Journal:  Cell Death Dis       Date:  2012-10-11       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.